^
    over1year
    Autologous huMNC2-CAR44 or huMNC2-CAR22 T Cells for Breast Cancer Targeting Cleaved Form of MUC1 (MUC1*) (clinicaltrials.gov)
    P1, N=69, Recruiting, Minerva Biotechnologies Corporation | Trial primary completion date: Jan 2023 --> Jan 2025
    Trial primary completion date • Metastases
    |
    HER-2 (Human epidermal growth factor receptor 2) • PGR (Progesterone receptor) • MUC1 (Mucin 1)
    |
    HER-2 positive • HR positive • HER-2 negative • HR negative • ER negative • MUC1 expression • HR positive + HER-2 negative
    |
    huMNC2-CAR22 • huMNC2-CAR44 CAR T cells